Cofactor Genomics

OverviewSuggest Edit

Cofactor Genomics uses RNA to diagnose disease. The Company works with the largest life-sciences and pharmaceutical companies in the world has resulted in Cofactor developing unique technologies and software that use RNA to inform disease.

Cofactor's team of experts boasts decades of collective experience working in the Technology Development Group at the Genome Center at Washington University in St. Louis, Missouri.

HQSan Francisco, US
Employee Ratings4.8

Latest Updates

Employees (est.) (Nov 2019)24(-4%)

Cofactor Genomics Office Locations

Cofactor Genomics has an office in San Francisco
San Francisco, US (HQ)
600 California St, San Francisco
Show all (1)

Cofactor Genomics Financials and Metrics

Summary Metrics

Founding Date


Cofactor Genomics total Funding

$20.8 m

Cofactor Genomics latest funding size

$18 m

Time since last funding

2 years ago

Cofactor Genomics investors

Cofactor Genomics's latest funding round in September 2017 was reported to be $18 m. In total, Cofactor Genomics has raised $20.8 m
Show all financial metrics

Cofactor Genomics Online and Social Media Presence

Embed Graph

Cofactor Genomics Blogs

Make Precision Medicine a Reality: Stop Drug Development

SAN FRANCISCO, Nov. 4, 2019 (FIERCEPHARMA) – Are more drugs really the answer to unlocking precision medicine? New focus that prioritizes patient profiling is likely to have major impact. The post Make Precision Medicine a Reality: Stop Drug Development appeared first on Cofactor Genomics.

The Complexity of PD-L1 Biology

By Kevin Flanagan, PhD PD-1 and PD-L1 inhibitors have growing importance in cancer treatment. Many tumors express PD-L1, a cell surface protein that binds to PD-1. PD-1 is expressed by T cells, an immune cell type important for fighting infections and cancer. When tumor PD-L1 binds to T cell PD-1, i…

Cofactor Genomics Opens Early Access to New T Cell Exhaustion Models through Predictive Immune Modeling Platform

— Announces “Functional to FFPE” Early-Access Grant Program —  San Francisco — November 6, 2019 (REPORTABLE) — Cofactor Genomics, leaders in RNA-based technologies and diagnostics, announced today they will provide early access to a new feature in their Predictive Immune Modeling platform which enab…

Multidimensional Biomarkers & Machine Learning Based Approaches for Precision Medicine

By Dave Messina As part of the Clinical Biomarkers & World CDx Conference held in Boston last month, I had the honor of moderating a panel on a fascinating and timely topic,  “Multidimensional Biomarkers & Machine Learning Based Approaches for Precision Medicine”. And what a panel — attendee…

Personalized Medicine through Predictive Immune Modeling

SAN FRANCISCO, Oct. 10, 2019 (CIOREVIEW) – Drug developers and clinicians are looking for a biomarker that can capture more of a patient’s immunological profile, their response to therapy, and potentially, the overall prognosis of health outcome. The post Personalized Medicine through Predictive Imm…

Multidimensional Biomarker Discovery with Steve Daniel, PhD

In our last interview, we spoke with John Kuelper, Managing Director at Ascension Ventures. We’re continuing to speak to industry experts to get their perspective on what’s going on with immune-oncology, precision and personalized medicine and where we may be headed over the next few years. In the f…
Show more

Cofactor Genomics Frequently Asked Questions

  • When was Cofactor Genomics founded?

    Cofactor Genomics was founded in 2008.

  • How many employees does Cofactor Genomics have?

    Cofactor Genomics has 24 employees.

  • Who are Cofactor Genomics competitors?

    Competitors of Cofactor Genomics include Innate Pharma, Synthace and DBV Technologies.

  • Where is Cofactor Genomics headquarters?

    Cofactor Genomics headquarters is located at 600 California St, San Francisco, San Francisco.

  • Where are Cofactor Genomics offices?

    Cofactor Genomics has an office in San Francisco.

  • How many offices does Cofactor Genomics have?

    Cofactor Genomics has 1 office.